Federal Register Notice: FDA has determined the regulatory review period for Akzo Nobel N.V.’s Raplon is 1,724 days for the extension of a patent which claims the human drug product. Raplon is indicated as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures. To view this notice, click here.
